Accolade
Financials
Estimates*
USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 170m | 310m | 363m | 414m | 467m | 532m | 601m |
% growth | 29 % | 82 % | 17 % | 14 % | 13 % | 14 % | 13 % |
EBITDA | (38.7m) | (129m) | 182m | (69.3m) | 16.6m | 33.2m | 56.4m |
% EBITDA margin | (23 %) | (42 %) | 50 % | (17 %) | 4 % | 6 % | 9 % |
Profit | (50.7m) | (123m) | (460m) | (99.8m) | (85.7m) | (73.2m) | (64.1m) |
% profit margin | (30 %) | (40 %) | (127 %) | (24 %) | (18 %) | (14 %) | (11 %) |
EV / revenue | 11.8x | 3.6x | 2.1x | 1.5x | 0.4x | 0.3x | 0.2x |
EV / EBITDA | -52.1x | -8.7x | 4.2x | -8.8x | 10.8x | 5.0x | 2.4x |
R&D budget | 50.0m | 83.7m | 101m | 99.2m | - | - | - |
R&D % of revenue | 29 % | 27 % | 28 % | 24 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$20.0m | Series A | ||
N/A | $4.0m | Debt | |
$16.9m | Series B | ||
$30.0m | Series D | ||
N/A | $2.8m | Series D | |
$22.5m | Series E | ||
$71.1m | Series E | ||
$50.0m | Series F | ||
$20.0m | Early VC | ||
N/A | $220m Valuation: $1.2b 12.7x EV/LTM Revenues -26.9x EV/LTM EBITDA | IPO | |
Total Funding | AUD361m |
Related Content
Recent News about Accolade
EditAccolade.com is a healthcare technology startup that aims to revolutionize the patient experience by combining traditional advocacy with modern technology. The company operates in the healthcare market, serving clients who are looking for a more streamlined and personalized healthcare experience.
Accolade's business model is centered around providing personal Health Assistants who guide patients through their healthcare journey. These Health Assistants are supported by a network of over 1000 top US physicians, ensuring that patients receive expert advice and care. The company also leverages advanced technology to provide predictive recommendations, smart applications, and seamless integrations, making the healthcare experience more efficient and connected.
The company generates revenue by offering its services to patients who are seeking a more personalized and efficient healthcare experience. Accolade also claims to save costs for its clients, with an average cost savings of $7k across musculoskeletal diagnoses.
Accolade's services result in improved treatment plans, with 90% of expert medical consults leading to better outcomes. The company also claims to improve treatment plans 60-70% of the time and to provide alternative diagnoses in up to 5% of consults.
In summary, Accolade.com is a healthcare technology startup that combines traditional advocacy with modern technology to provide a more personalized and efficient healthcare experience. The company operates in the healthcare market and generates revenue by offering its services to patients.
Keywords: Healthcare, Technology, Personal Health Assistants, Advocacy, Efficiency, Personalization, Cost Savings, Improved Treatment Plans, Alternative Diagnoses, Expert Medical Consults.